RXRA and cancer: Other cancer-, immune- and hepatotoxicity-related pathways were also identified to be related to most TAA treatment conditions, such as “p53 signaling”, “TGF-β signaling”, “MAPK signaling”, “PPARα/RXRα activation”, “Hepatic fibrosis/Hepatic stellate cell activation” and “Wnt signaling”.